BGM Group Ltd.
NASDAQ:BGM · NASDAQ Global Market
+$0.00 today
Vol 0.15M · Avg 0.51M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:BGM · Revenue to Net Income
No earnings data available.
Income Statement
Annual data · 5 periods
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.1M -46.0% | $46.5M -28.3% | $64.9M +13.6% | $57.1M +14.1% | $50.0M | $921.6M | $731.2M | $843.2M |
| Cost of Revenue | $21.0M -53.1% | $44.7M -23.7% | $58.6M +13.9% | $51.5M +21.1% | $42.5M | $804.0M | $882.4M | $1.3B |
| Gross Profit | $4.1M +134.9% | $1.8M -71.9% | $6.2M +10.4% | $5.6M -25.2% | $7.5M | $7.6B | $6.2B | $4.9B |
| Gross Margin | 16.4% +12.6pp | 3.8% -5.8pp | 9.6% -0.3pp | 9.9% -5.2pp | 15.1% | 28.9% | 38.3% | 12.3% |
| Research & Development | $1.4M +139.5% | $568.5K -53.6% | $1.2M | $0 | $0 | $1.3B | $490.4M | $1.1B |
| Selling, General & Admin | $3.3M -12.6% | $3.8M +30.8% | $2.9M -10.8% | $3.3M +19.2% | $2.7M | $923.0M | -$1.5B | $732.6M |
| Operating Expenses | $4.7M +7.3% | $4.4M +5.7% | $4.1M +26.9% | $3.3M +19.2% | $2.7M | $7.0B | $8.7B | $7.3B |
| Depreciation & Amortization | $1.2M +8.2% | $1.1M -6.7% | $1.2M +2.0% | $1.2M +2.8% | $1.2M | $1.2B | $631.8M | $1.5B |
| EBITDA | $879.9K +169.0% | -$1.3M -134.1% | $3.7M -9.9% | $4.2M -42.4% | $7.2M | $6.8B | $9.3B | $11.9B |
| EBITDA Margin | 3.5% +6.2pp | -2.7% -8.5pp | 5.8% -1.5pp | 7.3% -7.1pp | 14.4% | 46.3% | 42.0% | 37.7% |
| Operating Income | -$563.8K +78.4% | -$2.6M -224.2% | $2.1M -12.0% | $2.4M -50.4% | $4.8M | $14.0B | -$15.7B | $14.3B |
| Operating Margin | -2.2% +3.4pp | -5.6% -8.9pp | 3.2% -0.9pp | 4.2% -5.4pp | 9.6% | 24.1% | 22.0% | 29.5% |
| Interest Income | $0 -100.0% | $99.2K +299.0% | $24.9K | $0 | $0 | -$1.6B | $405.0M | $561.8M |
| Interest Expense | $639.5K | $0 | $0 -100.0% | $57.7K -76.3% | $242.9K | $1.0B | $1.2B | $1.3B |
| Other Income / Expenses | -$1.6M +70.3% | -$5.3M -877.5% | -$541.4K -155.5% | $975.2K -1.9% | $994.2K | $1.4B | $1.2B | $1.1B |
| Income Before Tax | -$2.1M +73.0% | -$7.9M -606.4% | $1.6M -53.6% | $3.4M -42.1% | $5.8M | $4.9B | $3.6B | $5.3B |
| Pre-Tax Margin | -8.5% +8.5pp | -17.0% -19.4pp | 2.4% -3.5pp | 5.9% -5.7pp | 11.6% | 18.7% | 26.2% | 24.1% |
| Income Tax Expense | -$620.0K -382.9% | $219.2K +12.8% | $194.3K -23.8% | $255.1K -70.5% | $864.9K | -$1.6B | $745.2M | $1.0B |
| Net Income | -$1.4M +81.5% | -$7.8M -822.6% | $1.1M -65.9% | $3.2M -37.7% | $5.1M | $4.8B | $4.7B | -$15.5B |
| Net Margin | -5.7% +11.0pp | -16.7% -18.4pp | 1.7% -3.9pp | 5.5% -4.6pp | 10.1% | 17.5% | 22.5% | 27.5% |
| EPS (Basic) | -$0 +81.5% | -$1 -820.0% | $0 -66.7% | $0 -37.5% | $1 | $703.2M | $1.3B | $512.8M |
| EPS (Diluted) | -$0 +81.5% | -$1 -820.0% | $0 -66.7% | $0 -37.5% | $1 | $609.4M | $452.6M | $598.2M |
| Weighted Avg Shares | $7.2M +0.0% | $7.2M +0.0% | $7.2M +6.0% | $6.8M -2.6% | $7.0M | $925.8M | $1.1B | $1.3B |
| Weighted Avg Shares (Diluted) | $7.2M +0.0% | $7.2M +0.0% | $7.2M +6.0% | $6.8M -2.6% | $7.0M | $924.4M | $678.0M | -$1.5B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector

Twist Bioscience Corporation
NASDAQ:TWST
$5.28B

Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.92B

Structure Therapeutics Inc.
NASDAQ:GPCR
$2.60B

Clover Health Investments, Corp.
NASDAQ:CLOV
$2.58B
Avadel Pharmaceuticals plc
AVDL
$2.12B

Mesoblast Limited
NASDAQ:MESO
$1.85B

ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
$1.82B

Phibro Animal Health Corporation
NASDAQ:PAHC
$1.28B

PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.21B

QuidelOrtho Corporation
NASDAQ:QDEL
$918.45M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BGM generate?
BGM Group Ltd. (BGM) reported $25.10M of revenue in fiscal 2024.
Is BGM profitable?
BGM Group Ltd. (BGM) reported -$1,442,830.00 of net income, with a net margin of -5.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.